142 related articles for article (PubMed ID: 37247929)
1. Possible False Results With cobas
Kanaoka K; Tamiya A; Inagaki Y; Taniguchi Y; Nakao K; Takeda M; Matsuda Y; Okishio K; Shimizu S
Anticancer Res; 2023 Jun; 43(6):2771-2776. PubMed ID: 37247929
[TBL] [Abstract][Full Text] [Related]
2. Comparison of next-generation sequencing and cobas EGFR mutation test v2 in detecting EGFR mutations.
Murakami S; Yokose T; Shinada K; Isaka T; Katakura K; Ushio R; Kondo T; Kato T; Ito H; Saito H
Thorac Cancer; 2022 Nov; 13(22):3217-3224. PubMed ID: 36203199
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of the Oncomine Dx Target Test multi-CDx system and the possibility of utilizing those original sequence data.
Saito A; Terai H; Kim TJ; Emoto K; Kawano R; Nakamura K; Hayashi H; Takaoka H; Ogata A; Kinoshita K; Ito F; Shigematsu L; Okada M; Fukushima T; Mitsuishi A; Shinozaki T; Ohgino K; Ikemura S; Yasuda H; Kawada I; Soejima K; Nishihara H; Fukunaga K
Cancer Med; 2024 Feb; 13(4):e7077. PubMed ID: 38457233
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the analytical performance between the Oncomine Dx Target Test and a conventional single gene test for epidermal growth factor receptor mutation in non-small cell lung cancer.
Sakaguchi T; Iketani A; Furuhashi K; Nakamura Y; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Taguchi O; Hataji O
Thorac Cancer; 2021 Feb; 12(4):462-467. PubMed ID: 33314600
[TBL] [Abstract][Full Text] [Related]
5. Clinical importance of the range of detectable variants between the Oncomine Dx target test and a conventional single-gene test for EGFR mutation.
Sakaguchi T; Iketani A; Esumi S; Esumi M; Suzuki Y; Ito K; Fujiwara K; Nishii Y; Katsuta K; Yasui H; Taguchi O; Hataji O
Sci Rep; 2023 Aug; 13(1):13759. PubMed ID: 37612335
[TBL] [Abstract][Full Text] [Related]
6. Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions.
Hirotsu Y; Nakagomi T; Nagakubo Y; Goto T; Omata M
Sci Rep; 2024 Jan; 14(1):1594. PubMed ID: 38238401
[TBL] [Abstract][Full Text] [Related]
7. Comparison of diagnostic performance between Oncomine Dx target test and AmoyDx panel for detecting actionable mutations in lung cancer.
Nagakubo Y; Hirotsu Y; Yoshino M; Amemiya K; Saito R; Kakizaki Y; Tsutsui T; Miyashita Y; Goto T; Omata M
Sci Rep; 2024 May; 14(1):12480. PubMed ID: 38816489
[TBL] [Abstract][Full Text] [Related]
8. Tumour content ratio matters for detecting epidermal growth factor receptor mutation by cobas test in small biopsies; a retrospective study.
Kogo M; Fujimoto D; Hosoya K; Nagata K; Nakagawa A; Tachikawa R; Yamashita D; Kitamura Y; Imai Y; Tomii K
BMC Cancer; 2020 Feb; 20(1):104. PubMed ID: 32028905
[TBL] [Abstract][Full Text] [Related]
9. Performance Characteristics of a Real-Time Polymerase Chain Reaction Assay for the Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Plasma Samples of Non-Small Cell Lung Cancer (NSCLC) Patients.
O'Donnell P; May T; DeMartin K; Ferguson J; Halait H; Wei W; Yu K; Scudder S
Mol Diagn Ther; 2020 Aug; 24(4):451-460. PubMed ID: 32406048
[TBL] [Abstract][Full Text] [Related]
10. Lung adenocarcinoma with EGFR L858R-K860I and L858R-L861F doublet mutations from which the L858R mutation is undetectable through the cobas EGFR mutation test v2.
Wu CH; Zhang MS; Huang YL; Cheng WH; Lai JY; Hsieh MS; Liao WY
Pathol Res Pract; 2024 May; 257():155304. PubMed ID: 38657557
[TBL] [Abstract][Full Text] [Related]
11. Comparison between next-generation sequencing and multiplex polymerase chain reaction assays for nonsmall-cell lung cancer molecular diagnosis.
Murakami S; Shinada K; Otsutsumi Y; Komine F; Yuan Y; Nakamura J; Katakura S; Kondo T; Kato T; Yokose T; Saito H
Cancer Med; 2024 Apr; 13(7):e7162. PubMed ID: 38572952
[TBL] [Abstract][Full Text] [Related]
12. The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).
Ramadhan HH; Taaban DF; Hassan JK
Asian Pac J Cancer Prev; 2021 Feb; 22(2):591-596. PubMed ID: 33639678
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
Papadimitrakopoulou VA; Han JY; Ahn MJ; Ramalingam SS; Delmonte A; Hsia TC; Laskin J; Kim SW; He Y; Tsai CM; Hida T; Maemondo M; Kato T; Jenkins S; Patel S; Huang X; Laus G; Markovets A; Thress KS; Wu YL; Mok T
Cancer; 2020 Jan; 126(2):373-380. PubMed ID: 31769875
[TBL] [Abstract][Full Text] [Related]
14. Feasibility of next-generation sequencing test for patients with advanced NSCLC in clinical practice.
Ariyasu R; Uchibori K; Ninomiya H; Ogusu S; Tsugitomi R; Manabe R; Sakamaoto H; Tozuka T; Yoshida H; Amino Y; Kitazono S; Yanagitani N; Takeuchi K; Nishio M
Thorac Cancer; 2021 Feb; 12(4):504-511. PubMed ID: 33350072
[TBL] [Abstract][Full Text] [Related]
15. A profile on cobas® EGFR Mutation Test v2 as companion diagnostic for first-line treatment of patients with non-small cell lung cancer.
Torres S; González Á; Cunquero Tomas AJ; Calabuig Fariñas S; Ferrero M; Mirda D; Sirera R; Jantus-Lewintre E; Camps C
Expert Rev Mol Diagn; 2020 Jun; 20(6):575-582. PubMed ID: 32011193
[TBL] [Abstract][Full Text] [Related]
16. Investigation of EGFR mutations in non-small cell lung cancer usually undetectable by PCR methods.
Matsubara T; Nakajima E; Namikawa H; Ono S; Takada I; Ohira T; Morishita Y; Miyazaki T; Furukawa K; Ikeda N
Mol Clin Oncol; 2022 Jan; 16(1):15. PubMed ID: 34881035
[TBL] [Abstract][Full Text] [Related]
17. The association of EGFR amplification with aberrant exon 20 insertion report using the cobas EGFR Mutation Test v2.
Zhang MS; Yeh YC; Huang HN; Lin LW; Huang YL; Wang LC; Yao LJ; Hung TC; Tseng YF; Lee YH; Liao WY; Shih JY; Hsieh MS
PLoS One; 2024; 19(4):e0301120. PubMed ID: 38687753
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.
Westwood M; Joore M; Whiting P; van Asselt T; Ramaekers B; Armstrong N; Misso K; Severens J; Kleijnen J
Health Technol Assess; 2014 May; 18(32):1-166. PubMed ID: 24827857
[TBL] [Abstract][Full Text] [Related]
19. EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer.
John T; Akamatsu H; Delmonte A; Su WC; Lee JS; Chang GC; Huang X; Jenkins S; Wu YL
Lung Cancer; 2018 Dec; 126():133-138. PubMed ID: 30527177
[TBL] [Abstract][Full Text] [Related]
20. Accuracy of the cobas EGFR Mutation Assay in Non-small-cell Lung Cancer Compared With Three Laboratory-developed Tests.
Nakamura H; Koizumi H; Sakai H; Kimura H; Miyazawa T; Marushima H; Saji H; Takagi M
Clin Lung Cancer; 2018 Mar; 19(2):170-174. PubMed ID: 29150249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]